Author's response to reviews

Title: FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer: results from FIRGEM study

Authors:

Aziz Zaanan (aziz.zaanan@gmail.com)
Isabelle Trouilloud (isabelle.trouilloud@apr.aphp.fr)
Theofano Markoutsaki (markoutsaki@yahoo.com)
Mélanie Gauthier (MGauthier@cgfl.fr)
Anne-Claire Dupont-Gossart (acgossartdupont@chu-besancon.fr)
Thierry Lecomte (thierry.lecomte@univ-tours.fr)
Thomas Aparicio (thomas.aparicio@avc.aphp.fr)
Pascal Artru (dr.artru@wanadoo.fr)
Anne Thirot-Bidault (anne.bidault@bct.aphp.fr)
Fanny Joubert (fanny.joubert1@gmail.com)
Daniella Fanica (fanicadani@yahoo.com)
Julien Taieb (julien.taieb@egp.aphp.fr)

Version: 2 Date: 13 July 2013

Author's response to reviews: see over
Cover letter

BMC cancer: 1225062775102764

Dear Editorial Board,

Please find our revised manuscript about our article entitled: “FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer: results from FIRGEM study”, by Aziz Zaanan and colleagues that we submitted in June 30th 2013 for publication in “BMC Cancer”.

As suggested by the editorial board, we addressed the comments in the revised manuscript and provide this cover letter to give a point-by-point response to the concerns.

1) Trial Registration Number

We notice that you are reporting a clinical trial but have not cited a trial registration number. This must be obtained before we can begin peer review of your manuscript. BioMed Central has always supported initiatives to improve the performance and reporting of clinical trials, part of which includes prospective registering and numbering of trials. BioMed Central requests a trial registration number for
manuscripts reporting work that falls within the International Committee of Medical Journal Editors (ICMJE) definition of a clinical trial: any research study that prospectively assigns human subjects to one or more health related interventions to evaluate the effects on health outcomes.

We would like you to confirm that your clinical trial is in a publicly accessible registry before we begin peer review. The trial registration number should be included as the last line of the abstract of the manuscript.

We confirm that our clinical trial is in a publicly accessible registry and we included the trial registration number as the last line of the abstract of the revised manuscript (marked in red):

“EudraCT : 2006-005703-34”

2) Details of ethical approvals at each participating site, including the names of all ethics committees who approved the study at each participating site.

We have added the following comment in the “Patients and methods” section of the revised manuscript: “This study was reviewed and approved by the Pitié-Salpêtrière hospital Ethics Committee for all centers” (marked in red).

3) Consent statement

Please state in the Methods section whether written informed consent for participation in the study was obtained from participants or, where participants are children, a parent or guardian.

We have added the following comment in the “Patients and methods” section of the revised manuscript: “All patients were aged more than 18 years and provided a signed written informed consent” (marked in red).
4) Acknowledgements

Please acknowledge anyone who contributed towards the article by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship. Please also include the source(s) of funding for each author, and for the manuscript preparation.

We have added the following comment in the “Acknowledgments” section of the revised manuscript:

“We thank the clinical research associates of different centers that participated in this study. Financial support for this research was provided by AGEO (Association des gastroentérologues oncologues / Gastroenterologists Oncologists Association).”

Sincerely,

Aziz ZAANAN, MD, PhD